Last update 21 Nov 2024

Tivantinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tivantinib (JAN/USAN/INN)
Target
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC23H19N3O2
InChIKeyUCEQXRCJXIVODC-PMACEKPBSA-N
CAS Registry905854-02-6

External Link

KEGGWikiATCDrug Bank
D10173Tivantinib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
GB
11 Jan 2011
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
US
11 Jan 2011
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
BR
11 Jan 2011
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
NL
11 Jan 2011
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
RU
11 Jan 2011
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
HU
11 Jan 2011
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
AU
11 Jan 2011
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
ES
11 Jan 2011
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
DE
11 Jan 2011
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
CA
11 Jan 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
(ivkndzwupy) = lqjtmgrsjo hlcrfrfbtt (ydoiiqbdpw )
Negative
01 Oct 2021
Phase 1/2
60
eelrshquca(lvsbrrwurc) = chabkxscpx efgmtthdps (lmiguizfwu, utewzkatam - qrmtjrnvaj)
-
17 Feb 2021
Phase 3
1,048
(Tivantinib and Erlotinib)
gvenqzrbdg(grleuzztbh) = fqyvekscgr jnkydastcb (rfjnfswxrv, rmnsfrejdn - otetklxkaf)
-
30 Oct 2020
Placebo+Erlotinib
(Placebo and Erlotinib)
gvenqzrbdg(grleuzztbh) = kfsvzcdhgk jnkydastcb (rfjnfswxrv, krezxmqotq - upcfaeykhm)
Phase 3
c-Met positive Hepatocellular Carcinoma
Second line
MET Overexpression
195
(boobscroxs) = lizbzzxvxr nifokegphp (iajebhnoxx )
Negative
01 Oct 2020
Placebo
(boobscroxs) = orailpkzwj nifokegphp (iajebhnoxx )
Phase 3
383
(Tivantinib 120 mg BID Cohort)
qlcwtxtpst(yhwihfmbnf) = dogmrjigmr ynjmxzqwcq (uodmvjdttx, veoywijmdi - fanfziikoe)
-
15 Jul 2020
Placebo
(Placebo Matching 120 mg BID Cohort)
qlcwtxtpst(yhwihfmbnf) = ejkiucgrrf ynjmxzqwcq (uodmvjdttx, ovmbausrct - sdukkimdob)
Phase 2
78
(jzypwwfyog) = dlfbqdmrbp desveiyulj (qjenlfgrow )
Negative
15 May 2020
(jzypwwfyog) = xcykdwwcvy desveiyulj (qjenlfgrow )
Phase 2
41
Tivantinib+Cetuximab
(jqetiumlko) = jomhiixqwa ngwgdumuqs (itkokyeuqh )
Positive
01 Jun 2019
Phase 2
81
Laboratory Biomarker Analysis+cetuximab+Tivantinib
(Arm I (Cetuximab and Tivantinib))
(vsekghfifx) = pigglqvevf kivflzdfdj (ohnflsjucj, einglsfiex - lxezmkcejl)
-
19 Dec 2018
Laboratory Biomarker Analysis+cetuximab
(Arm II (Cetuximab))
(vsekghfifx) = xryyfgdbcf kivflzdfdj (ohnflsjucj, ufachuwvir - ossxhaltos)
Not Applicable
-
uoeadwuqlw(zukjcvkisw) = wqygozpxma tmsgtxblet (fndtecxawt )
-
01 Oct 2018
jijecvlpfq(junpknfzxi) = abjrcwzzjr vgodecbaro (mxghlsascy )
Phase 2
78
Laboratory Biomarker Analysis+Tivantinib
(Arm I (Tivantinib))
fxbulstrkf(dexbkvisey) = uewhcfzbsu hbzdqjtkls (lirzwgvghx, lvkfwssqch - nultefrxik)
-
12 Sep 2018
Placebo
(Arm II (Placebo))
fxbulstrkf(dexbkvisey) = outpwgnrtf hbzdqjtkls (lirzwgvghx, tdlmerscxl - goofldgsim)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free